Back
  1. Home
  2. Profile of Séverine Andre (UMONS)
Profil

Andre Séverine

Main Referenced Co-authors
BURTEA, Carmen  (22)
LAURENT, Sophie  (22)
MULLER, Robert  (20)
Vander elst, Luce  (20)
Delcroix, Marie (8)
Main Referenced Keywords
General Neuroscience (4); blood-brain barrier (3); LDL receptor (3); peptides (3); Alzheimer's disease (2);
Main Referenced Unit & Research Centers
CMMI - Centre de Recherche en Microscopie et Imagerie Médicale (22)
UMHAP - Centre de Recherche UMONS-Ambroise Paré (1)
Main Referenced Disciplines
Neurology (12)
Biotechnology (12)
Zoology (12)
Immunology & infectious disease (11)
Pharmacy, pharmacology & toxicology (9)

Publications (total 22)

The most downloaded
38 downloads
TCHEOUBI, S. E. R., Andre, S., Laurent, S., & Burtea, C. (18 March 2019). Nouvelle Approche de Ciblage Moléculaire dans le Domaine de la Santé [Poster presentation]. Evénement de maillage UMONS-CHU Ambroise Paré (UMHAP), Mons, Belgium. https://hdl.handle.net/20.500.12907/32371

The most cited

95 citations (OpenCitations)

Andre, S., Verteneuil, S., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (13 May 2015). The targeting of phospholipase signaling and of LDL receptor aiming to develop a new therapeutic approach for Alzheimer's disease management [Poster presentation]. Bioforum 2015- ULG, Liège, Belgium. https://hdl.handle.net/20.500.12907/18418

Andre, S., Verteneuil, S., Ris, L., Kahvecioglu, Z. C., Nonclercq, D., De winter, J., Vander elst, L., Laurent, S., Muller, R., & Burtea, C. (29 December 2023). Modulation of Cytosolic Phospholipase A2 as a Potential Therapeutic Strategy for Alzheimer’s Disease. Journal of Alzheimer's Disease Reports, 7 (1), 1395-1426. doi:10.3233/adr-230075
Peer Reviewed verified by ORBi

Andre, S., Larbanoix, L., Verteneuil, S., Stanicki, D., Nonclercq, D., Vander Elst, L., Laurent, S., Muller, R., & Burtea, C. (05 June 2020). Development of an LDL receptor-targeted peptide susceptible to facilitate the brain access of diagnostic or therapeutic agents. Biology, 9, 161, 1-26. doi:10.3390/biology9070161
Peer reviewed

Burtea, C., Andre, S., & Laurent, S. (10 December 2019). Peptides binding to LDL receptor as carriers for crossing the blood-brain barrier.

Andre, S., Atakana Lukulu, J. M., Lecomte, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (28 October 2019). A promising phospholipase A2 targeted peptide slowing amyloid beta pathology in an Alzheimer's disease mouse model [Poster presentation]. the 2nd International Conference on Neurovascular and Neurodegenerative Diseases, Paris, France.

Andre, S., Atakana Lukulu, J. M., Lecomte, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (24 May 2019). Development of an original phospholipase A2-targeted peptide able to reduce amyloid pathology in a mouse model of Alzheimer's disease [Poster presentation]. 13th National Congress of the Belgian Society for Neuroscience, Brussels, Belgium. doi:10.3389/conf.fnins.2019.96.00032

TCHEOUBI, S. E. R., Andre, S., Laurent, S., & Burtea, C. (18 March 2019). Nouvelle Approche de Ciblage Moléculaire dans le Domaine de la Santé [Poster presentation]. Evénement de maillage UMONS-CHU Ambroise Paré (UMHAP), Mons, Belgium.

Andre, S., Lecomte, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (07 July 2018). Phospholipase A2 targeting for the development of an original therapeutic strategy in the context of Alzheimer's disease [Paper presentation]. 11th FENS Forum of Neuroscience, Berlin, Germany.

Andre, S., Lecomte, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (28 February 2018). Therapy of Alzheimer's disease: inhibitory potential of a phospholipase A2-targeted peptide able to cross the blood-brain barrier [Poster presentation]. Belgian peptide Group Meeting, Bruxelles, Belgium.

Andre, S., Ansciaux, E., Saidi, E., Larbanoix, L., Stanicki, D., Nonclercq, D., Vander Elst, L., Laurent, S., Muller, R., & Burtea, C. (07 November 2017). Validation by magnetic resonance imaging of the diagnostic potential of a heptapeptide-functionalized imaging probe targeted to amyloid beta and able to cross the blood-brain barrier. Journal of Alzheimer's Disease, 60 (4), 1547-1565. doi:10.3233/JAD-170563
Peer Reviewed verified by ORBi

Andre, S., Daldal, F., Lecomte, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (22 May 2017). The phospholipase A2 signaling as a new therapeutic biomarker of Alzheimer's disease: modulation through phage display-derived peptides able to cross the blood-brain barrier [Poster presentation]. 12th Meeting of the Belgian Neutoscience Society, Ghent, Belgium. doi:10.3389/conf.fnins.2017.94.00057

Andre, S., Daldal, F., Delcroix, M., Verteneuil, S., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (16 May 2017). Blood-brain barrier crossing for improving brain access using a peptide able to bind a receptor-mediated transcytosis [Paper presentation]. BMIC, Bruxelles, Belgium.

Andre, S., Daldal, F., Delcroix, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (10 April 2017). Towards the therapy of Alzheimer's disease via the inhibition of a phospholipase A2 isoform using peptides able to cross the blood-brain barrier [Poster presentation]. BNA 2017 : festival of neuroscience, Birmingham, United Kingdom.

Andre, S., Daldal, F., Delcroix, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (07 March 2017). Targeting phospholipase A2 for the treatment of Alzheimer's disease through a peptidic modulation [Poster presentation]. MDC : Mardi des Chercheurs 2017, Mons, Belgium.

Andre, S., Daldal, F., Delcroix, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (10 December 2016). Phospholipase A2 modulation in Alzheimer's disease: new approach of treatment using peptides able to accede to the brain through the LDL receptor [Poster presentation]. Joint meeting of the Belgian Neurological Society and Belgian Dementia Council (BeDeCo) December 10th 2016, Antwerp, University of Antwerp, Belgium.

Andre, S., Ansciaux, E., Larbanoix, L., Fanfone, D., Nonclercq, D., Vander Elst, L., Laurent, S., Muller, R., & Burtea, C. (29 November 2016). Targeting amyloid plaques for the early diagnosis of Alzheimer's disease: validation of a vectorized superparamagnetic contrast agent able to cross the blood-brain barrier [Poster presentation]. BMIC 'Imaging in Drug Discovery and development', Janssen Pharmaceutica, Beerse, Belgium.

Andre, S., Daldal, F., Delcroix, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (08 October 2016). New therapeutic management of Alzheimer's disease: interest to a phospholipase A2-targeted peptide able to cross the blood-brain barrier through the LDL receptor [Poster presentation]. Belgian Brain Congress, MICX. October 8, 2016, Mons, Belgium. doi:10.3389/conf.fnagi.2016.03.00046

Andre, S., Verteneuil, S., Delcroix, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (08 June 2016). Stratégie thérapeutique de la maladie d'Alzheimer par délivrance ciblée et modulation peptidique d'une phospholipase [Poster presentation]. 13ème RFMASA Réunion francophone sur la maladie d'Alzheimer et les syndromes apparentés. 8 au 10 juin 2016, Lyon, France.

Andre, S., Daldal, F., Delcroix, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (18 May 2016). Approche thérapeutique de la maladie d'Alzheimer : passage de la barrière hémato-encéphalique et modulation peptidique d'une phospholipase A2 [Poster presentation]. 9ème édition de la Matinée des Chercheurs 2016 (MdC2016); Mons; Belgique; 2015, Valenciennes, France.

Andre, S., Verteneuil, S., Delcroix, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (17 February 2016). Peptide-mediated modulation of a phospholipase isoform and blood-brain barrier transcytosis in the context of Alzheimer's disease therapy [Poster presentation]. Belgian Peptide Group Meeting, Bruxelles, Belgium.

Andre, S., Verteneuil, S., Delcroix, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (22 May 2015). Development of a new therapeutic approach for Alzheimer's disease by phospholipase pathway modulation and blood-brain barrier shuttling [Paper presentation]. 11th National Congress of the Belgian Society for Neuroscience, Mons, Belgium. doi:10.3389/conf.fnins.2015.89.00068

Andre, S., Verteneuil, S., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (13 May 2015). The targeting of phospholipase signaling and of LDL receptor aiming to develop a new therapeutic approach for Alzheimer's disease management [Poster presentation]. Bioforum 2015- ULG, Liège, Belgium.

Andre, S., Verteneuil, S., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (10 March 2015). Toward the development of a therapeutic strategy applied to Alzheimer's disease via phospholipase signaling [Poster presentation]. 8ème édition de la Matinée des Chercheurs 2015 (MdC2015), Mons, Belgium.

Contact ORBi UMONS